Urology News and Research

Latest Urology News and Research

ASI receives FDA clearance for GenASIs Scan and Analysis

Applied Spectral Imaging (ASI) announces that ASI's GenASIs automated scanning and image analysis system for detection and quantifying chromosome 17 and the HER-2/neu gene has been cleared by the United States Food and Drug Administration (FDA) for marketing in the US.

20 Feb 2012

Arsenic found in baby formula containing organic brown rice syrup

Rice is among the plants that are efficient in taking up arsenic from the soil, environmental chemist Brian Jackson of Dartmouth College in Hanover, N.H., and his co-authors said in Thursday's issue of the journal Environmental Health Perspectives. Long-term exposure to extremely high levels of inorganic arsenic can increase the risk of lung, liver and bladder cancer as well as miscarriage and infertility.

18 Feb 2012

OICR launches Phase III Active Surveillance Magnetic Resonance Imaging Study Trial

Dr. Nicole Onetto, Deputy Director and Chief Scientific Officer of the Ontario Institute for Cancer Research (OICR), today announced the launch of an innovative Phase III clinical trial that aims to determine whether multi-parametric magnetic resonance imaging (MRI) coupled with transrectal ultrasound (TRUS) guided biopsy (called fusion technology) can accurately identify men with prostate cancer who are at risk of developing aggressive disease.

18 Feb 2012

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

The arsenal of prostate cancer treatments for men with advanced prostate cancer may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer may be within reach.

18 Feb 2012

Thrombocytosis linked to severity of ovarian cancer

Highly elevated platelet levels fuel tumor growth and reduce the survival of ovarian cancer patients, an international team of researchers led by scientists at The University of Texas MD Anderson Cancer center reports in the New England Journal of Medicine.

16 Feb 2012

Study confirms increased risk of cancers linked with Lynch syndrome

People with Lynch syndrome have a genetic mutation that gives them a high risk of several types of cancer including bowel cancer. The genes that are damaged can't repair any errors that occur in our DNA.

15 Feb 2012

Bilateral nerve sparing helps retain orgasmic function after prostrate cancer surgery

The vast majority of men who have a prostate cancer operation can retain their ability to orgasm if the surgery is carried out without removing the nerves that surround the prostate gland like a hammock, according to a study in the February issue of the urology journal BJUI.

14 Feb 2012

U of A professor receives $542,000 from NSERC for drinking water research

Water is something people can't live without, that's why it's important that Xing Fang Li finds out what is in our tap water that may pose a disease risk. The researcher from the Faculty of Medicine & Dentistry at the University of Alberta just received $542,000 from the Natural Sciences and Engineering Research Council of Canada for drinking water research.

14 Feb 2012

People with Lynch syndrome face increased risks of breast and pancreatic cancers

A new prospective study of patients with Lynch syndrome - an inherited disorder of cancer susceptibility caused by mutations in specific DNA repair genes - provides the first strong evidence that people with Lynch syndrome face significantly increased risks of breast and pancreatic cancers.

14 Feb 2012

Progesterone vaginal gel 8% NDA transferred to Watson

Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced that Columbia has transferred the new drug application for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy (NDA 22-139) to Watson.

13 Feb 2012

ICN Food List for interstitial cystitis/bladder pain syndrome patients

When one cup of coffee, tea or cranberry juice can trigger days of pain and/or bladder discomfort, interstitial cystitis, overactive bladder and other urology patients often develop an unhealthy fear of food. A new iPhone and iPad application, (ICN Food List) seeks to change that by giving patients an easy to use food list and database that they can use while shopping and eating out at restaurants.

13 Feb 2012

Helmet fit, air bladder lining may be linked with concussion and intracranial hemorrhage

Concussions and the issues that can occur following one, continue to be a serious problem for football players. However, one simple game strategy: proper helmet fit, may be one of the easiest game winners for prevention, say researchers presenting their study at the American Orthopaedic Society for Sports Medicine's Specialty Day in San Francisco.

13 Feb 2012

Watson seeks FDA approval to market generic Beyaz

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg.

13 Feb 2012

Curcumin may block growth of castrate-resistant prostate tumors

Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy (ADT), a study from researchers at Jefferson's Kimmel Cancer Center suggests.

13 Feb 2012

Link between coronary artery disease and prostate cancer

In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.

8 Feb 2012

Watson settles ORTHO TRI-CYCLEN LO patent litigation with Janssen

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has reached a settlement with Janssen Pharmaceuticals, Inc. on outstanding patent litigation related to Watson's generic version of Janssen's ORTHO TRI-CYCLEN LO (norgestimate/ethinyl estradiol) tablets.

8 Feb 2012

Cefpodoxime not effective in treating uncomplicated cystitis in women

Short-term use of the antibiotic cefpodoxime for the treatment of women with uncomplicated cystitis (bladder infection) did not meet criteria for noninferiority for achieving clinical cure compared with ciprofloxacin, a drug in the fluoroquinolone class of antibiotics for which there have been concerns about overuse and a resulting increase in resistance rates, according to a study in the February 8 issue of JAMA.

8 Feb 2012

ED can lead to potential cardiovascular disease in men

More than 12 million men have type 2 diabetes and that number is growing at an alarming rate. A little talked about complication of this disease is erectile dysfunction (ED), which can lead to an even more serious condition.

7 Feb 2012

Wake Forest Baptist researchers create emergency general surgery registry

Researchers at Wake Forest Baptist Medical Center in Winston-Salem, NC, have successfully created and implemented an emergency general surgery registry (EGSR) that will advance the science of acute surgical care by allowing surgeons to track and improve surgical patient outcomes, create performance metrics, conduct valid research and ensure quality care for all emergency general surgery (EGS) patients.

7 Feb 2012

Watson: ANDA for generic Lidoderm remains on track

In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm patent challenge, Watson Pharmaceuticals, Inc. today issued the following statement: Watson's abbreviated new drug application (ANDA) for a generic version of Lidoderm remains on track.

4 Feb 2012